Get in touchPrescribing informationAE reporting
Prescribing informationAE reporting
HomeNeuroblastoma and the unmet needIndicationHeritage
The QARZIBA® story
Neuroblastoma and the unmet needIndicationHeritage
How QARZIBA® works
How immunotherapy worksQARZIBA®'s mechanism of action
How immunotherapy worksQARZIBA®'s mechanism of action
QARZIBA® efficacy and safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
Resources
Infusion & administrationDosing calculator
Infusion & administrationDosing calculatorGet in touchPrescribing Information
Terms of usePrivacy policyCookie policyContact
Home
The QARZIBA® story
Heritage

Heritage

QARZIBA® has a strong heritage of clinical experience and partnership and is the solid tumour immunotherapy developed in children – for children

From the first publication of preliminary data in 2010, to the present day, QARZIBA® has been part of the management plan for thousands of children with high-risk neuroblastoma.1,2

QARZIBA® is the SIOPEN-recommended standard of care for children with high-risk neuroblastoma in the maintenance setting.3-5

Approximate treatments completed worldwide:

9,700

Other pages in this section

Neuroblastoma and the unmet need

Indication

Heritage - footer

GL-DNB-2200035 | February 2023

Abbreviations

SIOPEN=Society of Paediatric Oncology European Neuroblastoma Network.

References

  1. Yu AL et al. N Engl J Med 2010; 363 (14): 1324–1334.
  2. Periodic Benefit-Risk Evaluation Report. Nov 2020 to Nov 2021. Data on file.
  3. Ladenstein R et al. Lancet Oncol 2018; 19: 1617–1629.
  4. Ladenstein R et al. Cancers 2020; 12: 309.
  5. QARZIBA® (dinutuximab beta). Summary of product characteristics.

This is a promotional website created by Recordati Rare Diseases and is intended for HCPs only.